Arcutis Biotherapeutics, Inc.
ARQT · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $2 | $0 | $1 | $1 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $0 | $1 | $1 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 229.7% | 1,517.1% | – | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 90.3% | 91.6% | 79.5% | – |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -55.8% | -381.6% | -7,991.1% | – |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -71.3% | -439.8% | -8,449.8% | – |
| EPS Diluted | -1.16 | -3.78 | -5.66 | -4.17 |
| % Growth | 69.3% | 33.2% | -35.7% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |